DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses

Information source: Hannover Medical School
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Abscess, Intra-Abdominal

Intervention: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Hannover Medical School

Official(s) and/or principal investigator(s):
Michael Winkler, Prof, Principal Investigator, Affiliation: Medical School Hannover, Department for abdominal and transplant surgery

Overall contact:
Michael Winkler, Prof, Phone: 0049-511-5324659, Email: Winkler.Michael@MH-Hannover.DE


The study is contemplating the antibiotic therapy of intraabdominal abscesses. These abscesses are a serious problem in surgical practice. Associated pathophysiologic effects as for example peritonitis may become life threatening or may lead to extended periods of morbidity with prolonged hospitalization. The objective of the sudy is to evaluate whether the combination of Moxifloxacin and Metronidazole is equivalent to Piperacillin / Tazobactam with regard to clinical outcome and eradication of aerobe and anaerobe pathogens in patients with intra-abdominal abscesses.

Clinical Details

Official title: Single Centre, Prospective, Comparative, Open-label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Clinical success / failure rate at the Test-of-Cure visit

Secondary outcome:

Clinical + Bacteriological response at End-of-Treatment-visit

Time to discharge from hospital

Course of disease on the basis of clinical and laboratory parameters

safety and tolerability of the study medication

cost effectiveness of treatment regimes

Detailed description: The study is an interventional prospective, comparative, open-label, randomised single-centre study. Adult patients with intra-abdominal abscesses matching the criteria to be included will be enrolled in the study and randomised into one of the Groups: 1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily. Primary study endpoints: Clinical success / failure rate at the Test-of-Cure visit.

Secondary study endpoints: - Bacteriological response at TOC, -Clinical + Bacteriological

response at End-of-Treatment-visit, - Course of disease on the basis of clinical and

laboratory parameters, - Time to discharge from hospitals, -Duration of hospitalization

post-operatively, - safety and tolerability of the study medication, -cost effectiveness of

treatment regimes.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients who attained full age (18 years) with intra-abdominal abscesses documented

by: A) Laparotomy revealing intra-abdominal abscess or macroscopic gastrointestinal perforation OR B) Suspected intra-abdominal abscess and scheduled for operation with at least three of the following criteria:

- fever,

- leucocytosis,

- symptoms referable to the abdominal cavity (nausea, pain),

- tenderness with or without rebound / abdominal wall rigidity,

- radiological evidence for abscess or gastrointestinal perforation.

Exclusion Criteria:

- Patients with the following:

- indwelling peritoneal catheter,

- presumed spontaneous bacterial peritonits,

- peripancreatic sepsis or infection secondary to pancreatitis,

- peptic or traumatic perforation of gastrointestinal tract of < 24 h duration,

- traumatic perforation of the small or large bowel of < 12h duration,

- transmural necrosis of the intestine due to acute embolic, thrombotic or

obstructive occlusions,

- acute cholecystitis,

- appendicitis without perforation or abscess,

- required open abdomen techniques for management,

- gynaecological infection,

- known hypersensivity to any of the study drugs,

- lifethreatening disease with life expectancy of less than 48 hours,

- neutropenia with neutrophil count < 1000 cells/µl,

- receiving chronic treatment with imunosuppressant therapy,

- HIV-seropositives with CD4 count < 200 cells/µl,

- end stage hepatic cirrhosis CHILD PUGH C,

- central or peripheral neuropathy,

- bradycardia,

- symptomatic dysrhythmia in medical history,

- syndromes of QTc prolongation or use of concomittant medicaments reported to

increase QT interval,

- disorder of the electrolyte balance,

- previous history of tendinopathy with quinolones,

- previously enrolled in the trial or use of any investigational drug within the

previous 30 days

Locations and Contacts

Michael Winkler, Prof, Phone: 0049-511-5324659, Email: Winkler.Michael@MH-Hannover.DE

Medical School Hannover, Hannover 30625, Germany; Recruiting
Beate Heins-Hoentsch, Phone: 0049-511-5326924
Additional Information

Starting date: November 2005
Last updated: June 21, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017